ABOUT CAMURUS PRODUCTS PIPELINE TECHNOLOGIES INVESTORS MEDIA CONTACT ENGLISH CAMURUS PRODUCTS Addressing important unmet medical needs Camurus' products are based on our proprietary FluidCrystal® technologies and are designed to address important unmet medical needs, with the potential to make a significant difference in the daily life of patients by improving treatment outcomes, quality of life, and long-term recovery. BUVIDAL® PROLONGED-RELEASE SOLUTION FOR INJECTION Buvidal® buprenorphine injection depots are indicated for the treatment of opioid dependence within a framework of medical, social and psychological treatment, and intended for use in adults and adolescents aged 16 years or over. For more information, please visit buvidal.com EPISIL® ORAL LIQUID Effective oral pain relief Oral mucositis is a painful inflammation and ulceration of the oral mucosa. It is a common and painful side effect of radiotherapy and chemotherapy. For more information, see episil.net episil® oral liquid is a medical device for treatment of inflammatory and painful conditions in the oral cavity. The product provides fast pain relief and protection of sore and inflamed mucosal surfaces, as well as severe inflammation caused by e.g. oral mucositis, a common and serious side effect of cancer treatment. In contact with the buccal membrane, episil® transforms into a thin protective layer of gel, offering effective pain relief for up to 8 hours. episil® oral liquid is based on Camurus’ FluidCrystal® topical bioadhesive technology. episil - Key publications Effects of a bioadhesive barrier-forming oralliquid on pain due to radiation-induced oralmucositis in patients with head and neckcancer: A randomized crossover,preliminary study Soutome, S., et al., Journal of Dental Sciences (2021) 16:96-100 Local analgesic effect of a bioadhesive barrier-forming oral liquid in cancer patients with oral mucositis caused by chemotherapy and/or radiotherapy: a randomized multicenter, single-use, positive-controlled, open-label study Cheng, Y., et al., OncoTargets and Therapy (2018) Nov 30;11:8555-64 Camurus AB Ideon Science Park. SE-223 70 Lund, Sweden. Visiting address Ideongatan 1A. 223 62 Lund, Sweden. Phone: +46 46 286 57 30 Fax: +46 46 286 57 39 Email addresses General enquiries: info@camurus.com Business Development: busdev@camurus.com Media: media@camurus.com Investor Relations: ir@camurus.com ABOUT CAMURUS PRESENTATIONS PIPELINE PRODUCTS TECHNOLOGIES INVESTORS CAREER LEGAL NOTICE PRIVACY CONTACT IR CONTACT By continuing to use the site, you agree to the use of cookies. more information Accept